Supplementary Figure 2 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer

Supplementary Figure 2 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer

<p>Supplementary Figure 2. Proportion of samples with PD-L1 TPS ≥1%, ≥50%, ≥90% according to ATM mutation status (ATMMUT versus ATMWT).</p>

Сохранить в:
Библиографические подробности
Главный автор: Biagio Ricciuti (14951247) (author)
Другие авторы: Arielle Elkrief (15055750) (author), Joao Alessi (15561455) (author), Xinan Wang (15561458) (author), Yvonne Li (15561461) (author), Hersh Gupta (15561464) (author), Daniel M. Muldoon (15561467) (author), Arrien A. Bertram (14954848) (author), Federica Pecci (15561470) (author), Giuseppe Lamberti (15024714) (author), Alessandro Di Federico (15561473) (author), Adriana Barrichello (15561476) (author), Victor R. Vaz (15561479) (author), Malini Gandhi (15561482) (author), Elinton Lee (15561485) (author), Geoffrey I. Shapiro (14961801) (author), Hyesun Park (15561488) (author), Mizuki Nishino (15561491) (author), James Lindsay (15032271) (author), Kristen D. Felt (15561494) (author), Bijaya Sharma (15561497) (author), Andrew D. Cherniack (14959412) (author), Scott Rodig (15561500) (author), Daniel R. Gomez (15561503) (author), Narek Shaverdian (15561506) (author), Mehrdad Rakaee (15561509) (author), Chaitanya Bandlamudi (15047205) (author), Marc Ladanyi (15050661) (author), Pasi A. Janne (15561512) (author), Adam J. Schoenfeld (15022025) (author), Lynette M. Sholl (15032729) (author), Mark M. Awad (14961722) (author), Michael L. Cheng (15561515) (author)
Опубликовано: 2025
Предметы:
Cancer
Molecular and Cellular Biology
Cancer Detection and Diagnosis
Therapeutic Research and Development
Clinical Research and Trials
Biomarkers
Genetic biomarkers
DNA Damage and Repair
DNA repair
Lung Cancer
Precision Medicine
Translational Research
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!
Описание
Итог:<p>Supplementary Figure 2. Proportion of samples with PD-L1 TPS ≥1%, ≥50%, ≥90% according to ATM mutation status (ATMMUT versus ATMWT).</p>

Схожие документы